Cancer gene therapy with HSV- tk / GCV system depends on T- cell - mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer. 1999;83:374 - 380.Shigeki K,Masaji K,Kazuhiro M, et al.Cancer Gene thrapy with HSV-tk/GCV system depends on T-cell-...
Since the introduction of molecular analysis, the increased frequency of presymptomatic diagnosis of eye complication resulted in more effective laser therapy. Prognosis (please For renal cancers, the likelihood of potential cure and of describe) the prevention of metastases has improved the prog- nosis...
Beyond the standalone application of gene therapy described earlier, combining siRNA and CRISPR-based gene therapy approaches with immunotherapies or chemotherapies holds significant promise to enhance anti-tumour responses and overcome drug resistance. For instance, silencing KRAS mutations using siRNA has ...
We reasoned that tumour stroma, including vascular endothelial cells, would consequently experience transient hypoxia that may allow transcriptional targeting as part of an antivascular gene therapy approach to cancer. To exploit hypoxia for transcriptional regulation, retroviral vectors were generated with ...
Gene Therapy – Tumour‐suppressor Gene Replacement/Oncogene Suppression First page of article Keywords: gene therapy of cancer; tumour-suppressor gene replacement; oncogene suppression; p53; Ras JA Roth,SF Grammer - John Wiley & Sons, Ltd 被引量: 1发表: 2005年 ELF5 is an epithelial-specific ...
Progress and Promise of Epigenetics for Diagnosis and Therapy in Cancer LiliLiao, ...HaifengYang, inCancer Genetics, 2015 PBRM1is another key tumor suppressor in kidney cancer AlthoughVHLis frequently mutated in ccRCC and has been shown to be essential to development in this disease, it is a ...
51. Osaka M, Rowley JD, Zeleznik-Le NJ: MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci USA 1999, 96:6428-6433. One of the earliest reports on the Sept9-MLL gene fusion in...
The enhancer of zeste homolog 2 (EZH2) and its highly related homolog EZH1 are considered to be epigenetic silencing factors, and they play key roles in the growth and differentiation of cells as the core components of polycomb repressive complex 2 (PRC2
Rapid advances in cancer gene therapy are driven by an explosive development of gene transfer technology and a strong demand for seeking alternatives to un
The findings could have important clinical implications, as this type of prostate cancer, in which the PTEN tumor-suppressor gene is inactivated, accounts for about 40 to 50 percent of primary prostate cancers and 70 to 90 percent of cancers that become resistant to hormone therapy. New finding...